DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

计划入组 390 人 · 首次发布于 2026 年 4 月 22 日

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

计划入组 204 人 · 首次发布于 2023 年 5 月 31 日

Continued Access to RXDX-105

计划入组 3 人 · 首次发布于 2018 年 12 月 21 日

RXDX-106

RXDX-104

RXDX-108

Metsera

Ecora Resources PLC

United States

DYNAMIC ACTIVE TACTICAL BOND ETF UNITS

Precision Medicine Market Projected to Reach $456.81 Billion by 2035, Driven by AI Diagnostics and National Genomics Programs

Roche's VENTANA FOLR1 RxDx Assay Receives CE Mark for Ovarian Cancer Treatment Selection

Roche's VENTANA FOLR1 RxDx Assay Receives CE Mark for Ovarian Cancer Diagnosis